Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 2
2018 5
2019 4
2020 3
2021 8
2022 7
2023 8
2024 11
2025 8
2026 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

53 results

Results by year

Filters applied: . Clear all
Page 1
Safety of New Biologics (Vedolizumab and Ustekinumab) and Small Molecules (Tofacitinib) During Pregnancy: A Review.
Gisbert JP, Chaparro M. Gisbert JP, et al. Drugs. 2020 Jul;80(11):1085-1100. doi: 10.1007/s40265-020-01346-4. Drugs. 2020. PMID: 32562207 Review.
Just a few studies including patients treated with vedolizumab or ustekinumab during pregnancy have been published, reporting uneventful pregnancies in most cases. ...There is no evidence of adverse effect of vedolizumab or ustekinumab pa …
Just a few studies including patients treated with vedolizumab or ustekinumab during pregnancy have been published, rep …
Maternal and Neonatal Outcomes in Vedolizumab- and Ustekinumab-Exposed Pregnancies: Results From the PIANO Registry.
Chugh R, Long MD, Jiang Y, Weaver KN, Beaulieu DB, Scherl EJ, Mahadevan U. Chugh R, et al. Am J Gastroenterol. 2024 Mar 1;119(3):468-476. doi: 10.14309/ajg.0000000000002553. Epub 2023 Oct 5. Am J Gastroenterol. 2024. PMID: 37796648
The objective of this study was to provide information from the Pregnancy Inflammatory bowel disease And Neonatal Outcomes registry on maternal and fetal outcomes in patients exposed to the newer biologics ustekinumab (UST) and vedolizumab (VDZ). ...Continuat …
The objective of this study was to provide information from the Pregnancy Inflammatory bowel disease And Neonatal Outcomes registry o …
British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults.
Lamb CA, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK, Hayee B, Lomer MCE, Parkes GC, Selinger C, Barrett KJ, Davies RJ, Bennett C, Gittens S, Dunlop MG, Faiz O, Fraser A, Garrick V, Johnston PD, Parkes M, Sanderson J, Terry H; IBD guidelines eDelphi consensus group; Gaya DR, Iqbal TH, Taylor SA, Smith M, Brookes M, Hansen R, Hawthorne AB. Lamb CA, et al. Gut. 2019 Dec;68(Suppl 3):s1-s106. doi: 10.1136/gutjnl-2019-318484. Epub 2019 Sep 27. Gut. 2019. PMID: 31562236 Free PMC article.
Safety of Ustekinumab and Vedolizumab During Pregnancy-Pregnancy, Neonatal, and Infant Outcome: A Prospective Multicentre Study.
Mitrova K, Pipek B, Bortlik M, Bouchner L, Brezina J, Douda T, Drasar T, Klvana P, Kohout P, Leksa V, Minarikova P, Novotny A, Svoboda P, Skorpik J, Ulbrych J, Veinfurt M, Zborilova B, Lukas M, Duricova D; Czech IBD Working Group. Mitrova K, et al. J Crohns Colitis. 2022 Dec 5;16(12):1808-1815. doi: 10.1093/ecco-jcc/jjac086. J Crohns Colitis. 2022. PMID: 35708729 Free article.
No significant difference in pregnancy outcome between either the vedolizumab or the ustekinumab group and controls was observed [p >0.05]. ...The median infant-to-maternal ratio of ustekinumab levels was 1.67 and it was 0.59 in vedolizumab. …
No significant difference in pregnancy outcome between either the vedolizumab or the ustekinumab group and controls was …
Safety of Vedolizumab and Ustekinumab Compared With Anti-TNF in Pregnant Women With Inflammatory Bowel Disease.
Meyer A, Miranda S, Drouin J, Weill A, Carbonnel F, Dray-Spira R. Meyer A, et al. Clin Gastroenterol Hepatol. 2025 Jan;23(1):144-153.e22. doi: 10.1016/j.cgh.2023.12.029. Epub 2024 Jan 8. Clin Gastroenterol Hepatol. 2025. PMID: 38199301
We applied a propensity score matching for maternal, IBD, and pregnancy characteristics. RESULTS: Three hundred ninety-eight pregnancies exposed to vedolizumab were compared with 1592 pregnancies exposed to anti-TNF; 464 pregnancies exposed to …
We applied a propensity score matching for maternal, IBD, and pregnancy characteristics. RESULTS: Three hundred ninety-eight pregn …
Differences in the placental pharmacokinetics of vedolizumab and ustekinumab during pregnancy in women with inflammatory bowel disease: a prospective multicentre study.
Mitrova K, Pipek B, Bortlik M, Bouchner L, Brezina J, Douda T, Drasar T, Drastich P, Falt P, Klvana P, Leksa V, Novotny A, Svoboda P, Skorpik J, Ulbrych J, Veinfurt M, Zborilova B, Lukas M, Duricova D. Mitrova K, et al. Ther Adv Gastroenterol. 2021 Aug 7;14:17562848211032790. doi: 10.1177/17562848211032790. eCollection 2021. Ther Adv Gastroenterol. 2021. PMID: 34394725 Free PMC article.
We aimed to assess the placental transfer of ustekinumab and vedolizumab in pregnant patients with inflammatory bowel disease. METHODS: Consecutive women from a prospective observational study who were exposed to ustekinumab or vedolizumab within 2 mon …
We aimed to assess the placental transfer of ustekinumab and vedolizumab in pregnant patients with inflammatory bowel disease. …
Pairwise Comparative Safety and Effectiveness of Anti-TNF Blockers, Vedolizumab, and Ustekinumab During Pregnancy: A Systematic Review and Meta-Analysis.
Segun-Omosehin O, Bourdakos NE, Tzanis KG, Macaron MM, Jamal F, Marks L, Hamad A, Malik TA. Segun-Omosehin O, et al. Dig Dis Sci. 2026 May 25. doi: 10.1007/s10620-026-09948-w. Online ahead of print. Dig Dis Sci. 2026. PMID: 42183927 Review.
PURPOSE: Biologic therapies, including tumor necrosis factor (TNF) blockers, vedolizumab (VDZ), and ustekinumab (UST), are generally considered safe during pregnancy in patients with inflammatory bowel disease (IBD), though comparative data remain limited. .. …
PURPOSE: Biologic therapies, including tumor necrosis factor (TNF) blockers, vedolizumab (VDZ), and ustekinumab (UST), are gen …
Vedolizumab and Ustekinumab Levels in Pregnant Women With Inflammatory Bowel Disease and Infants Exposed In Utero.
Prentice R, Flanagan E, Wright EK, Gibson PR, Rosella S, Rosella O, Begun J, An YK, Lawrance IC, Kamm MA, Sparrow M, Goldberg R, Prideaux L, Vogrin S, Kiburg KV, Ross AL, Burns M, Bell SJ. Prentice R, et al. Clin Gastroenterol Hepatol. 2025 Jan;23(1):124-133.e7. doi: 10.1016/j.cgh.2024.02.025. Epub 2024 Mar 15. Clin Gastroenterol Hepatol. 2025. PMID: 38492905
BACKGROUND & AIMS: Vedolizumab and ustekinumab pharmacokinetics in pregnancy and the infant after in utero exposure remain incompletely defined. ...CONCLUSIONS: Maternal vedolizumab levels decreased, whereas ustekinumab levels remained stabl …
BACKGROUND & AIMS: Vedolizumab and ustekinumab pharmacokinetics in pregnancy and the infant after in utero exposure …
Pharmacokinetics of Monoclonal Antibodies Throughout Pregnancy: A Systematic Literature Review.
van Gendt J, Emaus R, Visschedijk MC, Touw DJ, Bouwknegt DG, de Leeuw K, Prins JR, Malik P, Mian P. van Gendt J, et al. Clin Pharmacokinet. 2024 May;63(5):589-622. doi: 10.1007/s40262-024-01370-7. Epub 2024 Apr 7. Clin Pharmacokinet. 2024. PMID: 38583128 Free PMC article.
BACKGROUND AND OBJECTIVE: Although little information is available on the pharmacokinetics (PK) of monoclonal antibodies (mAbs) during pregnancy, multiple mAbs are being used during pregnancy for various indications. The aim of this systematic literature review was …
BACKGROUND AND OBJECTIVE: Although little information is available on the pharmacokinetics (PK) of monoclonal antibodies (mAbs) during pr …
53 results